نتایج جستجو برای: eluting stents outcome assessment

تعداد نتایج: 903119  

Journal: :Circulation. Cardiovascular interventions 2015
Tobias Koppara Qi Cheng Kazuyuki Yahagi Hiroyoshi Mori Oscar David Sanchez Julia Feygin Eric Wittchow Frank D Kolodgie Renu Virmani Michael Joner

BACKGROUND Acute thrombogenicity and re-endothelialization represent clinically relevant end points pertaining to the safety of coronary stents, which have not been compared among biodegradable polymer-based drug-eluting metallic stents and fully bioabsorbable scaffolds to date. METHODS AND RESULTS We investigated comparative outcomes with respect to acute thrombogenicity and re-endothelializ...

2016
Alev Arat Ozkan Umit Yasar Sinan Aziz T Gurmen

Stent fracture is a rare complication of drug-eluting stent implantation with a reported rate of 0.84%-3.2% in various clinical studies with first-generation drug-eluting stents and 29% in autopsy studies. Sirolimus-eluting stents with their closed cell design were reported to be more prone to fracture compared to paclitaxel-eluting stents. Other risk factors for stent fracture are multiple ste...

Journal: :The European journal of cardiovascular medicine 2010
Kamal Chitkara Kushal Pujara

Over the past decade, the advent of drug-eluting stents (DES) has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for repeat revascularisation. A number of stents capable of delivering an anti-proliferative agent designed to prevent neointimal hyperplasia, the principal mechanism of restenosis after stent...

Journal: :Arquivos brasileiros de cardiologia 2005
Cristiana Marques de Araujo Gustavo Adolfo B Rando Maria Fernanda Z Mauro Salvador A B Cristóvão Isaac S Moscoso Sanchez Adnan Ali Salman João B de Oliveira Neto José Armando Mangione

OBJECTIVE The excellent results obtained with sirolimus (rapamicin)-eluting stents for preventing restenosis have motivated the evaluation of other substances with that property. Batimastat is a highly effective metalloproteinase enzyme blocker, with the potential to reduce the degradation of extracellular matrix and to inhibit the migration of smooth muscle cells, with the consequent capacity ...

Journal: :Circulation. Cardiovascular interventions 2017
Ahmed N Mahmoud Amr F Barakat Akram Y Elgendy Erik Schneibel Amgad Mentias Ahmed Abuzaid Islam Y Elgendy

BACKGROUND Data regarding the long-term efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents are limited. This meta-analysis aimed to compare the long-term outcomes with both devices. METHODS AND RESULTS Randomized trials reporting clinical outcomes beyond 1 year and comparing BVS with everolimus-eluting stents were included....

Journal: :The American journal of cardiology 2006
Flavio Airoldi Carlo Briguori Ioannis Iakovou Goran Stankovic Giuseppe Biondi-Zoccai Mauro Carlino Alaide Chieffo Matteo Montorfano John Cosgrave Iassen Michev Renata Rogacka Giuseppe Massimo Sangiorgi Antonio Colombo

In patients with in-stent restenosis (ISR) inside bare metal stents, drug-eluting stents reduce the recurrence of restenosis compared with balloon angioplasty. However, few data are available about this therapeutic modality in the case of diffuse restenosis. The aim of this study was to evaluate the immediate and mid-term outcome of sirolimus- and paclitaxel-eluting stent implantation in diffus...

Journal: :Journal of the American College of Cardiology 2008
Eloi Marijon Xavier Jouven

Cardiol 2007;50:1305–9. 2. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193–202. 3. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231–6. 4. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to ...

2016
Shabnam Rashid

The risk of stent thrombosis and restenosis with the second generation drug eluting stents remains. The bioresorbable vascular scaffold is a third generation stent and overcomes the problems associated with drug eluting metallic stents. The bioresorbable vascular scaffold completely absorbs within the coronary vessel over 3-5 years. Multiple trials in patients with non complex coronary disease ...

Journal: :Circulation journal : official journal of the Japanese Circulation Society 2008
Shinji Kanemitsu Keizo Tanaka Jin Tanaka Hitoshi Suzuki Toshihiko Kinoshita

Two cases of drug-eluting stent restenosis after percutaneous coronary intervention in the left main coronary artery and its bifurcation are presented. An off-pump coronary artery bypass grafting following in-stent restenosis was performed. Drug-eluting stents have shown a reduced frequency of in-stent restenosis and a good safety profile compared with bare metal stents. However, intervention w...

Journal: :Circulation. Cardiovascular interventions 2013
Raul Moreno Eulogio García Rui Teles Jose-Ramon Rumoroso Henrique Cyrne Carvalho Francisco Javier Goicolea José Moreu Josefa Mauri Manel Sabaté Vicente Mainar Lino Patricio Mariano Valdés Felipez Fernández Vázquez Angel Sánchez-Recalde Guillermo Galeote Santiago Jimenez-Valero Manuel Almeida Esteban Lopez de Sa Luis Calvo Ignacio Plaza Jose-Luis Lopez-Sendón Jose-Luis R Martín

BACKGROUND Patients with coronary total occlusions are at especially high risk for restenosis and new revascularizations. Sirolimus-eluting stents dramatically improved the clinical outcome of this subset of patients in randomized trials, but other drug-eluting stents, mainly the everolimus-eluting stent (currently the most frequently used stent), have not yet been evaluated in patients with co...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید